The Angiomax bill -- does it stand a chance?

According to analyst Andrew Parmentier (Friedman, Billings Ramsey, left), the odds on the Angiomax patent term extension bill passing successfully through all its legislative stages are "still less than 50 per cent". The bill may have had a smooth passage through the House of Representatives but it still has to make it through the Senate and win the signature of the President. "We advise investors not to blindly interpret this event in the House as patent relief for Angiomax," said Parmentier in a note to investors: "we continue to see road-blocks in the Senate" [Source: CNNMonet.com].